{"id":3961,"date":"2006-04-04T23:59:00","date_gmt":"2006-04-04T23:59:00","guid":{"rendered":"https:\/\/bm.dev.synology.me\/?p=3961"},"modified":"2026-04-02T08:29:29","modified_gmt":"2026-04-02T08:29:29","slug":"29-martie-2006-tranzactia-terapia-ranbaxy-270-mil-euro","status":"publish","type":"post","link":"https:\/\/bm.dev.synology.me\/?p=3961","title":{"rendered":"29 MARTIE 2006 TRANZACTIA TERAPIA-RANBAXY 270 MIL. EURO"},"content":{"rendered":"<p><P class=text style=\"MARGIN: 0cm 0cm 0pt\" align=justify>Ranbaxy Laboratories, cel mai mare producator de medicamente generice din <?xml:namespace prefix = st1 ns = \"urn:schemas-microsoft-com:office:smarttags\" \/><st1:country-region w:st=\"on\"><st1:place w:st=\"on\">India<\/st1:place><\/st1:country-region>, a cumparat pentru 324 milioane de dolari (270 mil. euro) un pachet de 96,7% din actiunile Terapia, aflat in proprietatea companiei de investitii Advent. In urma acestei tranzactii &#8211; cea mai mare ca valoare de anul acesta din <st1:country-region w:st=\"on\"><st1:place w:st=\"on\">Romania<\/st1:place><\/st1:country-region> &#8211; Ranbaxy va intra in top 5 al companiilor farmaceutice de pe piata romaneasca.<\/P><?xml:namespace prefix = o ns = \"urn:schemas-microsoft-com:office:office\" \/><o:p><SPAN class=text>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><o:p>&nbsp;<\/o:p><\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>Terapia<\/STRONG><\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><o:p>&nbsp;<\/o:p><\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>ANUL INFIINTARII:<\/STRONG> 1921<\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>REZULTATE FINANCIARE:<\/STRONG> Anul trecut, Terapia a avut o cifra de afaceri de 67 mil. euro, din care aproape 10 mil. euro exporturi. <\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>ESTIMARI:<\/STRONG> Pentru acest an, Terapia si-a propus depasirea pragului de 100 mil. $ (circa 85 mil. euro). Din combinarea afacerilor fabricii clujene cu cele ale Ranbaxy, oficialii estimeaza vanzari de aproape 110 mil. euro in 2006.<\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>ANGAJATI:<\/STRONG> 950<\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>PRODUSE:<\/STRONG> Cel mai cunoscut brand al Terapia este Faringosept. Compania mai fabrica alte 156 de produse si este cel mai mare exportator de medicamente din <st1:country-region w:st=\"on\"><st1:place w:st=\"on\">Romania<\/st1:place><\/st1:country-region>.<\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>EXTINDERE:<\/STRONG> A cumparat in vara anului trecut doua firme &#8211; Pharmaplant si Promedic.<\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>PLUS:<\/STRONG> Este singurul producator roman care are centru de studii de bioechivalenta (care atesta ca un medicament generic are aceleasi efecte ca si produsul original, fara de care un medicament nu poate fi introdus pe piata UE).<\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><o:p>&nbsp;<\/o:p><\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>Ranbaxy<\/STRONG><\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><o:p>&nbsp;<\/o:p><\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>ANUL INFIINTARII:<\/STRONG> 1961<\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>REZULTATE FINANCIARE:<\/STRONG> In 2005, Ranbaxy a realizat vanzari de 1,18 mld. $, din care 25% in <st1:place w:st=\"on\"><st1:country-region w:st=\"on\">India<\/st1:country-region><\/st1:place> si 17% in Europa.<\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>ESTIMARI:<\/STRONG> Este in primii zece producatori mondiali de generice si si-a propus ca, pana in 2012, sa intre in top 5, cu vanzari de 5 mld. $.<\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>EXTINDERE:<\/STRONG> Strategia de dezvoltare presupune atat cresterea organica, in special pe piata SUA si pe cateva piete emergente, cat si prin achizitii. Preluarile joaca un rol cheie in strategia Ranbaxy, mai ales cand pot consolida o pozitie deja solida pe o anumita piata.<\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>ANGAJATI:<\/STRONG> 9.000<\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>PRODUCTIE:<\/STRONG> Compania indiana are capacitati de productie in sapte tari, iar produsele sale sunt comercializate in 125 de tari. <\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>IN <st1:country-region w:st=\"on\"><st1:place w:st=\"on\">ROMANIA<\/st1:place><\/st1:country-region>:<\/STRONG> A intrat recent pe piata autohtona, anul trecut realizand vanzari de peste 10 mil. euro si o cota de piata de circa 1,1%. In prezent, compania are aici 79 de angajati.<\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><o:p>&nbsp;<\/o:p><\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>Strategia<\/STRONG><\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><o:p>&nbsp;<\/o:p><\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>INTEGRARE:<\/STRONG> Din reunirea operatiunilor Ranbaxy cu ale Terapia va rezulta cea mai mare forta de vanzare din domeniul farmaceutic din <st1:country-region w:st=\"on\"><st1:place w:st=\"on\">Romania<\/st1:place><\/st1:country-region>. Se vor combina si pipe-line-urile (liniile de produse in pregatire) ale celor doua firme.<\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG><\/STRONG>&nbsp;<\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>HUB REGIONAL:<\/STRONG> Terapia va fi o platforma pentru intrarea Ranbaxy pe pietele regionale si pe cele europene. Terapia are un departament de inregistrare a produselor foarte bine pus la punct.<\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG><\/STRONG>&nbsp;<\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>SINERGII:<\/STRONG><SPAN style=\"mso-spacerun: yes\">&nbsp; <\/SPAN>Reprezentantii producatorilor sustin ca se vor realiza economii de costuri (in utilizarea capacitatilor de productie, achizitia de materii prime, studii de bioechivalenta), dar si cresteri ale veniturilor (prin accesul produselor Terapia la reteaua Ranbaxy, combinarea fortei de vanzari si introducerea pe piata romaneasca a mai multor medicamente Ranbaxy).<\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG><\/STRONG>&nbsp;<\/P>  <P class=MsoNormal style=\"MARGIN: 0cm 0cm 0pt\" align=justify><STRONG>PIATA AUTOHTONA:<\/STRONG> Piata romaneasca are una dintre cele mai ridicate cresteri din Europa, iar Ranbaxy isi propune sa devina numarul unu in <st1:country-region w:st=\"on\"><st1:place w:st=\"on\">Romania<\/st1:place><\/st1:country-region>. Vor urma, probabil, alte achizitii.<\/P><\/SPAN><\/o:p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ranbaxy Laboratories, cel mai mare producator de medicamente generice din India, a cumparat pentru 324 milioane de dolari (270 mil. euro) un pachet de 96,7% din actiunile Terapia, aflat in proprietatea companiei de investitii Advent. In urma acestei tranzactii &#8211; cea mai mare ca valoare de anul acesta din Romania &#8211; Ranbaxy va intra in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[698],"tags":[3302],"class_list":["post-3961","post","type-post","status-publish","format-standard","hentry","category-cover-story","tag-29-martie-2006-tranzactia-terapia-ranbaxy-270-mil-euro"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/3961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3961"}],"version-history":[{"count":1,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/3961\/revisions"}],"predecessor-version":[{"id":25395,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/3961\/revisions\/25395"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}